Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | MLNR | O43193 | 6/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.42 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495666 | 0.92 | HPGDS (0.55) | HPGDSSRCMLNRWNT3ADRD2 | |
| SCHEMBL16495485 | 0.92 | SRC (0.50) | HPGDSSRCDRD2DRD4TPSAB1 | |
| SCHEMBL16496171 | 0.90 | HPGDS (0.53) | HPGDSSRCMLNRWNT3ADRD2 | |
| SCHEMBL16495584 | 0.90 | SRC (0.53) | HPGDSSRCMLNRHDAC1HDAC8 | |
| SCHEMBL16496317 | 0.88 | HPGDS (0.56) | HPGDSSRCTPSAB1TPSD1TPSG1 | |
| SCHEMBL16495774 | 0.81 | MCHR1 (0.45) | HPGDSSRCMLNRHDAC1HDAC8 | |
| SCHEMBL1366908 | 0.81 | HPGDS (0.41) | HPGDSSRCWNT3ADRD2DRD4 | |
| SCHEMBL16495915 | 0.81 | SRC (0.51) | HPGDSSRCDRD2DRD4TPSAB1 | |
| SCHEMBL16496114 | 0.80 | SSTR3 (0.45) | HPGDSSRCMLNRTPSAB1TPSD1 | |
| SCHEMBL16496138 | 0.80 | SRC (0.49) | HPGDSSRCDRD2DRD4TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885SRC 4371/4885MLNR 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.